ImmunityBio develops immunotherapy treatments for cancer and infectious diseases.
ImmunityBio's IL-15 superagonist expands T and NK cell counts and cytotoxicity, creating a platform where engineered cells can be layered on top to target specific pathogens and tumors, analogous to Nvidia's role in AI infrastructure but for the immune system in the longevity-as-a-service stack.